Dr. Sylvain Garciaz is a
physician-scientist specializing in hematology. He did his medical school at
Marseille University in France and his Ph.D. at the Marseille Cancer Research
Center focusing on AML resistance to therapeutics. In 2019, he was awarded a
post-doctoral fellowship in the Mark Dawson’s Lab at PeterMac Callum Cancer
Centre in Melbourne. His scientific work focuses on resistance to BH3 mimetics
in acute myeloid leukemia and new therapeutics. From 2019 to the present, he is
an Associate Professor at Paoli-Calmettes Institute in Marseille, Coordinator of the Labeled Early Phase Trials Center ( CLIP²).
Dr. Yves Collette holds a Ph.D. in Virology from the
Free University of Bruxelles in Belgium. Dr. Collette completed a post-doctoral
internship in Onco-immunology in Marseille with the support of a European
Community Fellowship and was then recruited as a researcher by INSERM in 1998,
Research Associate at the Institut Paoli Calmettes (2008) and INSERM Research
Director (2008). As a researcher at the Cancer Research Centre of Marseille
(CRCM), an INSERM/CNRS/Aix Marseille University & Institut Paoli Calmettes
(IPC) Comprehensive Cancer Research Center), Dr. Collette’s main objectives are
to explore novel reservoirs of therapeutic targets in oncology and to develop new
integrated approaches in personalized medicine. Dr. Collette is currently
co-head of the CRCM Integrated Structural and Chemical Biology (ISCB) Team,
head of the TrGET Preclinical Platform, coordinator of the 18 CRCM CoreTech
technological resources, and scientific coordinator for the CRCM and the IPC.
Prof. Norbert Vey is a Professor of Hematology at the Aix-Marseille University, General Director of the Paoli Calmettes Institute. He completed his Ph.D. studies at the Aix-Marseille
University, Marseille, France, in 1994. His research interests include leukemia, genetic aberration,
and myeloproliferative neoplasm.
